Thursday - October 30, 2025
AstraZeneca: Update on the Resolute Phase III Trial for Fasenra in Chronic Obstructive Pulmonary Disease
September 18, 2025
WILMINGTON, Delaware, Sept. 18 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

Update on the RESOLUTE Phase III trial for FASENRA in chronic obstructive pulmonary disease

The RESOLUTE Phase III trial of AstraZeneca's did not achieve statistical significance in the primary endpoint in patients with chronic obstructive pulmonary disease (COPD)./i

Sharon Barr, Executive Vice President, BioPharmaceuticals . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products